GlassScriptPhysician profile
Pradnya Mitroo
NPI 1538371901
$48,104.33
in general payments reported to CMS, 2019-2025
36 companies · $6,578 in 2025
The $6,578 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,672 · 2020: $4,495 · 2021: $3,706 · 2022: $5,303 · 2023: $9,961 · 2024: $14K · 2025: $6,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $4,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,925.00 |
| Food and Beverage | $4,002.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28,174.14 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $11,702.17 | 2019-2024 | Linzess |
| Allergan, INC. | $4,149.86 | 2019-2020 | |
| Boston Scientific Corporation | $674.48 | 2019-2025 | Axios, General - Hemostasis, Spyglass |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $540.43 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $463.03 | 2019-2024 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $422.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $360.43 | 2022-2025 | Ibsrela |
| Celgene Corporation | $256.45 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $232.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.73 | 2025 | Dupixent |
| Olympus America INC. | $131.20 | 2024 | Single Use Aspiration Needle Na-U200h |
| Takeda Pharmaceuticals U.S.A., INC. | $123.50 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $73.10 | 2019-2022 | |
| Daiichi Sankyo INC. | $70.44 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $69.24 | 2019 | |
| Nestle Healthcare Nutrition INC. | $56.43 | 2022-2023 | |
| Qol Medical, LLC | $46.71 | 2023-2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $42.55 | 2025 | Iqirvo |
| Shionogi INC | $37.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.53 | 2024 | Voquezna |
| Orphalan INC | $30.54 | 2025 | Cuvrior |
| Genzyme Corporation | $25.86 | 2022-2023 | |
| Micro-Tech Endoscopy USA, INC. | $25.14 | 2023-2025 | Riteclip, Lockado |
| Lilly USA, LLC | $24.69 | 2025 | Omvoh |
| Vivus LLC | $24.17 | 2022 | |
| Novo Nordisk INC | $22.71 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $22.54 | 2024 | Idacio |
| Shire North American Group INC | $20.78 | 2019 | |
| Albireo Pharma, INC. | $18.93 | 2024 | Bylvay |
| Intercept Pharmaceuticals, INC. | $18.58 | 2020 | |
| Pfizer INC. | $17.81 | 2019 | |
| Celltrion USA INC. | $17.30 | 2024 | Vegzelma |
| Alfasigma USA, INC. | $15.60 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.87 | 2022 | |
| Endo Pharmaceuticals INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradnya Mitroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.